Kelly Dooley, ECCMID 2021: New drugs and Regimens for Treating Drug-resistant Tuberculosis
We met with Kelly Dooley (Johns Hopkins University School of Medicine, Baltimore, MD, USA) to discuss the new drugs and developing treatment regimens for drug-resistant tuberculosis.
The session entitled: ‘New drugs and new regimens for treating drug-resistant tuberculosis’ was presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- What are the most important second wave drugs for the treatment of tuberculosis, and what advantages do they offer over older drugs? (0:25)
- Could you tell us a little about the NixTB clinical trial, its findings and their impact on clinical practice? (2:48)
- What biomarkers seem useful in the development of drugs and regimens? (5:39)
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the 31st ECCMID Congress 2021.
Share this Video
Related Videos In Bacterial Infections
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]
Kayla Stover Hielscher, IDWeek 2022: Linezolid as a treatment option for MRSA bacteraemia
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is one of the more severe forms of MRSA. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss the use of linezolid as a treatment option for MRSA bacteraemia infection. Dr Stover Hielscher discusses drug interactions, […]
Michael Ison: Highlights from IDWeek 2022
In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics. Interviews available in this series: Respiratory syncytial virus (RSV) – Health burden […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!